



ALASKA STATE LEGISLATURE

Representative Genevieve Mina

Chair, House Health and Social Services Committee

Serving House District 19: Airport Heights, Mountain View, & Russian Jack

House Bill 195 ver I Sectional Analysis (34-LS0909\I) 02.25.26

"An Act relating to the prescription and administration of drugs and devices by pharmacists; relating to reciprocity for pharmacists; and providing for an effective date."

Section 1. Adds a new section AS 08.02.150 Regulation of collaborative practice agreements to prohibit the department or a board from requiring fees, prior approval, or defining the specific scope of patient care services provided under a collaborative practice agreement.

Section 2. Amends AS 08.80.030(b) Powers and duties of the board to update the board's powers to include establishing standards for the independent prescribing and administration of vaccines and opioid overdose drugs, and to require that a licensed pharmacist who prescribes, administers, or dispenses certain controlled substances register with the controlled substance prescription database (PDMP).

Section 3. Amends AS 08.80.110 Qualifications for licensure by examination to require that an applicant for licensure receive education in pain management and opioid use and addiction, unless they demonstrate they do not hold a valid federal DEA registration number.

Section 4. Amends AS 08.80.145 Reciprocity; license transfer to require that a pharmacist applying for licensure via reciprocity meet the same opioid and pain management education requirements established in AS 08.80.110(5).

Section 5. Amends AS 08.80.165 Continuing education requirements to require at least two hours of education in pain management and opioid use and addiction during each licensing period. A licensee is exempt if their practice does not include opioid prescription/administration or if they do not hold a federal DEA registration.

Section 6. Amends AS 08.80.337(a) Other patient care services to clarify that a collaborative practice agreement must be approved by a practitioner who is not a pharmacist and that the agreement itself defines the nature and scope of the services provided.

Section 7. Amends AS 08.80.337(b) Other patient care services to expand the conditions under which a pharmacist may independently provide services, including for minor/self-limiting conditions, provided the pharmacist uses a CLIA-waived test to guide the diagnosis or clinical decision.



ALASKA STATE LEGISLATURE

Representative Genevieve Mina

Chair, House Health and Social Services Committee

Serving House District 19: Airport Heights, Mountain View, & Russian Jack

Section 8. Amends AS 08.80.337(d) Other patient care services to define "patient care services" as medical care services intended to achieve outcomes related to the cure, prevention, or slowing of a disease, excluding the prescription of most controlled substances except when used for treating opioid use disorder in a clinic.

Section 9. Adds a new subsection to AS 08.80.337 Other patient care services (e) requiring that a pharmacist prescribing or administering a drug or device recognize the limits of their education, training, and experience and refer to other practitioners as appropriate.

Section 10. Amends AS 08.80.480(30) Definitions to update the definition of "practice of pharmacy" to explicitly include independent prescribing and the provision of patient care services in accordance with AS 08.80.337.

Section 11. Adds a new paragraph to AS 08.80.480 Definitions. (40) Adds a definition for "opioid" to include opium and opiate substances and derivatives as listed in state criminal statutes.

Section 12. Repeals AS 08.80.337(c) Other patient care services. To align with the updated independent practice and diagnostic testing provisions.

Section 13. Provides for an effective date of January 1, 2027.